ESC 2022 | REVIVED-BCIS2

The REVIVED-BCI2 included 700 patients with ejection fraction 35% with extended coronary artery disease and plausible PCI.

ESC 2022

Patients were randomized to PCI plus optimal and complete medical treatment (OMT) according to the current guidelines.

347 patients received PCI and 353 OMT.

Primary end point was all cause death and hospitalization for cardiac failure. 

There were no differences between the populations.

At 11-month follow-up, there were no differences in primary end point (PCI 37.2% vs OMT 38%). Neither were there differences in primary end point components or the presence of AMI. 

The need for unplanned revascularization and myocardial ischemia were more frequent in patients receiving OMT.

Ejection fraction at 2 years was 27% at 6 and 12 months with no difference between the strategies. 

Read also: ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function.

Quality of life, according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), was superior in patients receiving PCI at 6 months but with no difference at 2 years. 

We can conclude that this study on patients with severe ventricular dysfunction undergoing OMT at maximal tolerable doses, revascularization with PCI did not result in lower incidence of all cause death or hospitalization for cardiac failure. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....